Pharmaceutical Executive April 12, 2024
Pharma companies and RPM manufacturers must work together to find solutions to make DCT more commonly available.
For years, the pharmaceutical industry has known that decentralized trials, in which participants don’t have to attend many visits sessions at traditional clinical sites, can have profound positive effects. But when designing trials, pharma companies have had understandable concerns. Anytime a new medicine or therapy is being developed, it’s crucial to track patients for a slew of potential side effects, some of which could have consequences. So, trial sponsors have been wary of going substantial periods of time without monitoring these participants in person.
Now, the rapid growth of RPM (remote patient monitoring) solutions is changing the paradigm. An influx of technologies is...
Today's Sponsors
Today's Sponsor